RA Capital Management

RA Capital Management is a thesis-driven, evidence-based multi-stage investment firm focused primarily on healthcare and life sciences, investing across private and public markets from company formation through commercialization. The firm underwrites scientific and technical validation rather than company age, using deep internal research capabilities such as TechAtlas and incubation through Raven to build high-conviction positions globally.

Evaluation weights

How much weight this investor places on each dimension. Totals 100%.

Product-led · 37%

Metrics

18%

Revenue, growth, and unit economics

Market

30%

Size, timing, and competitive landscape

Team

15%

Founder experience and execution ability

Product

37%

Differentiation and technical quality

Strong bias toward evidence and falsifiable milestones over stage labels
Willingness to write very large checks when internal conviction is high
Preference for complex science that can be underwritten through deep diligence
Avoids ambiguous validation stories and late-stage risk without clear de-risking path

Pitch difficulty

How hard it is to get a meeting and close funding from this investor.

Funded / yr

Deals closed in a typical year.

Led / yr

Rounds led in the last 12 months.

Pitches / yr

~1200

Decks reviewed in a typical year.

Acceptance rate

2.0%

Share of pitches that get funded.

Estimated — public data is not fully disclosed.

Why it's hard

Deep research-led underwriting via TechAtlas and iterative diligence
High bar for scientific/technical validation and clear next milestones
Avoidance of ambiguous, long-duration, late-stage risk without clean evidence
Concentrated ability to lead very large rounds only when conviction is exceptional

RA Capital is highly selective because it combines broad stage flexibility with unusually deep, thesis-driven diligence and reserves large capital commitments for opportunities with exceptional scientific validation and a crisp path to further de-risking. Its focus on internal conviction, data quality, and milestone clarity makes the bar especially high even though the firm can invest across many stages.

Green flags

What drives a yes for this investor.

Strong scientific or technical validation with credible supporting data
A clear, time-bounded and capital-efficient path to the next validation milestone
Large healthcare or life-science opportunity with differentiated underlying science
Conviction generated through deep internal research and assumption-testing
Management teams capable of executing through clinical, regulatory, and commercial inflection points

Red flags

What kills deals and gets a fast no.

Unclear or speculative validation pathway with no decisive next experiment or trial
Relying on post-hoc or weak evidence to justify a major late-stage bet
Capital needs that are huge relative to the amount of risk retired
Subsidy-dependent economics, especially in Planetary Health opportunities
Management teams that are opaque, defensive, or unable to engage deeply on the data

How to win

Patterns that lead to successful pitches.

Lead with the core data package and explain exactly what has been validated already
Show a milestone-based financing plan that ties capital to uncertainty reduction
Demonstrate why the science or product is genuinely differentiated versus alternatives
Present a realistic regulatory, clinical, or commercialization path rather than a broad vision deck
Bring a syndicate and governance approach compatible with long-term, evidence-based company building

Fund strategy & identity

Who they are and how they operate.

Invests across the full company lifecycle from discovery to public-market follow-ons
Anchors or participates in large private rounds when scientific conviction is strong
Evaluates opportunities by validation status and the time/capital needed to reach key inflection points
Uses equity, debt, royalty, and hybrid structured capital solutions for later-stage situations
Maintains global scope with no strict geographic constraints

Firm identity

Evidence-based healthcare and life-science specialist Multi-stage investor spanning private and public markets High-conviction, flexible check writer and deal structure provider Research-heavy firm with internal diligence infrastructure via TechAtlas Company formation and incubation participant through Raven

Investment focus

Industries, themes, and typical ARR expectations.

Industries

Biopharma and therapeuticsMedical devicesDiagnosticsHealthcare servicesResearch tools and life-science infrastructureAI-enabled biotech platformsPlanetary Health technologies

Investment themes

Novel therapeutics and next-generation drug modalitiesCell therapy, in-vivo engineering, and precision oncologyAI-enabled drug discovery and biology platformsMedical devices, diagnostics, services, and research toolsClear regulatory and clinical validation pathways in biotechCommercial-stage healthcare companies with strong evidence basePlanetary Health solutions in critical minerals, energy, manufacturing, agriculture, and environmental services

Typical check by stage

Seed$1M-$10M

Series A$20M-$60M

Series B$30M-$75M

Series C$10M-$50M

Growth$25M-$75M

Typical ARR by stage

Pre Seed$0

Seed$0

Series A$0

Series B$0

Series C$0

Growth$0-$10M

Investment thesis

Core beliefs and strategy behind their investing approach.

RA Capital Management is a multi‑stage venture capital firm that concentrates on healthcare and life‑science companies, including drugs, medical devices, diagnostics, services, and research tools. It invests across the full lifecycle—from discovery and company formation (through its Raven incubator) to commercialization and public markets—both in private and public securities. The firm’s thesis‑driven, evidence‑based process evaluates how validated a concept is and the time‑and‑capital required to achieve validation, rather than relying solely on company stage. Geographically, its portfolio spans the globe, with no strict regional limits. In addition to healthcare, RA has launched a Planetary Health Fund that targets capital‑efficient, market‑driven solutions in critical minerals, energy, manufacturing, agriculture, and environmental services, seeking near‑term deployment and profitability without heavy reliance on subsidies. Core beliefs include originating conviction through data‑driven analysis (TechAtlas), challenging assumptions, and maintaining flexibility to change views. RA avoids investments where validation pathways are unclear or where companies rely heavily on policy subsidies, and it steers clear of late‑stage, high‑risk bets that lack a clear route to commercial validation.

Decision patterns

How they evaluate and make investment decisions.

RA Capital invests when a company demonstrates strong scientific or technical validation and a clear, data‑driven path to further validation, emphasizing the amount of time and capital required to reach that point. The first meeting, typically led by a TechAtlas associate, gathers high‑level context; a second, often confidential meeting refines the view of what data are needed to reach a decision, and the process can be compressed to one‑to‑two weeks for time‑sensitive deals. Deal‑breakers include late‑stage, high‑risk scenarios such as a public company pursuing a Phase 3 trial based on post‑hoc analysis of a failed Phase 2 study, or any situation where the validation pathway is ambiguous. In early diligence, technology, data, and business model dominate; as the process advances, the team places increasing weight on the founders and management team, especially when RA intends to take board seats or provide operational support. The firm prefers co‑investors who conduct deep diligence and can write large checks, aligning with its long‑term value‑creation focus and reducing the likelihood of short‑term exit pressure.

Risk appetite

RA Capital demonstrates an aggressive, high‑conviction risk posture. It is prepared to invest from the seed stage through commercial‑stage financings, including IPOs and follow‑ons, and can lead, co‑lead, or participate as a follower. Check sizes vary from sub‑$1 million in early seed rounds to more than $75 million in a single round, and the firm has taken ownership stakes as high as 30 % of a public company. The launch of its Structured Capital platform, which offers equity, debt, royalty, and hybrid solutions, further illustrates comfort with later‑stage credit and structured risk. While flexible, the firm applies a rigorous, data‑driven diligence process to ensure that large exposures are only made when conviction is strong.

Notable investments

Key portfolio companies and why they fit the thesis.

Capstan TherapeuticsLead
In‑vivo CAR‑T platform with strong scientific upside; RA led a large Series B to advance pipeline translation.
Outpace BioLead
AI‑powered cell therapy engineering for solid tumors; RA led the $144M Series B to drive first‑in‑human progress.
Superluminal MedicinesLead
Generative biology/chemistry/ML “membrane” company; RA led the $120M Series A, matching its platform biotech focus.
ILiAD BiotechnologiesLead
Next‑gen whooping cough vaccine; RA led the $115M Series B to support pivotal development.
Slate MedicinesLead
Anti‑PACAP migraine prevention therapies; RA co‑led the $130M Series A to advance a novel pathway.
Convergent TherapeuticsLead
Radiopharmaceuticals for solid tumors; RA co‑led the $90M Series A, aligning with its radiopharma track record.
EvommuneLead
Chronic inflammatory disease pipeline; RA co‑led the $115M Series C to scale clinical programs.
IDRxLead
Precision oncology targeting GIST; RA led the $120M Series B, a classic precision‑oncology leadership round.
Pahr TherapeuticsLead
Platform for pulmonary arterial hypertension; RA co‑led the $14M Seed, showing early‑stage company building.
Ventricle HealthLead
Virtual cardiology care network; RA led the $8M Seed, illustrating selective health‑tech bets with clinical impact.

Key people

Partners who lead investments and shape the thesis.

PK
Peter Kolchinsky
Managing Partner
Firm leadershipBiotech/therapeutics investing
RS
Rajeev Shah
Managing Partner
Firm leadershipPublic/private healthcare investing
DD
Derek DiRocco, PhD
Partner
Public and private investmentsSolid tumor oncology
JS
Jake Simson, PhD
Partner
Public and private investmentsSolid tumor oncology
J(
Joshua (Josh) Resnick, MD
Partner; President, Raven (RA Ventures)
Company formation (Raven)Early-stage therapeutics

Public voice

Notable statements and public positions.

“We are dedicated to evidence‑based investing in public and private healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools.” – RA Capital website
“We judge how investible a company is not by the maturity of the company itself but by how validated the concept is and, if not validated, how much time and money it will take to validate it… we might not invest in a public company that is running a five‑year Phase 3 trial with a novel mechanism based on a post‑hoc analysis of a failed Phase 2 study.” – RA Capital FAQ
“Superluminal’s platform and team have demonstrated success, and we are pleased to continue to support the company’s further growth and development.” – Andrew Levin, MD, PhD, Partner & Managing Director, RA Capital (on leading Superluminal’s $120 M Series A)

Similar investors

Firms with overlapping stage and industry focus.

OrbiMed 1.0%

Shared focus

DiagnosticsMedical Devices

Bain Capital Ventures 1.5%

6 shared stages